radical prostatectomy (RP) but does not include multiparametric pelvic MRI (mpMRI). Here, we evaluate the utility of mpMRI in predicting sXRT failure after RP.
INTRODUCTION AND OBJECTIVES: To examine the patterns of distant recurrence in patients with biochemical failure after treatment with brachytherapy for prostate cancer.
METHODS: We identified 4,036 patients treated with brachytherapy with or without external beam radiation (EBRT) and/or androgen deprivation therapy (ADT) for their diagnosis of prostate cancer. These patients were treated between 1992 to 2012 at a single institution. Of those patients, 266 had a PSA recurrence as defined by the Phoenix criteria. Of those patients, 92 were found to have distant failure as defined by metastases to bones, visceral organs, or lymph nodes. Kaplan Meier analysis was used to estimate 5-year freedom from distant failure. Univariable and multivariable cox regression analysis was performed to identify factors associated with distant failure.
RESULTS: Median age on presentation for our cohort was 67.5 with a median Gleason score of 7 and PSA of 9.3 ng/ml. We identified a 5-year freedom from distant failure rate of 65.7% with a median follow up of 8.17 years and a median time to BCR of 2.9 years after initial treatment with brachytherapy. Of those patients with distant metastases, 73.9% of patients showed metastases to the bone alone, 16.3% showed metastases to lymph nodes alone, 3.2% showed metastases to visceral organs alone, and 6.5% exhibited multiple sites of metastatic spread simultaneously. On multivariate analysis, Gleason score was significantly associated with increased risk of distant failure (HR¼1.30, P¼.045).
CONCLUSIONS: Patients who experience distant metastatic disease after BCR following brachytherapy are most likely to exhibit metastatic disease to bones, although metastases to visceral organs and lymph nodes were also observed. Gleason score was significantly associated with increased risk of distant failure. Our study is the first to look at patterns of metastatic recurrence within a cohort of patients specifically treated with brachytherapy as the primary modality for prostate cancer therapy. The above findings can be used when counseling patients with prostate cancer who are seeking brachytherapy treatment as well as when considering which imaging modalities to obtain for detection of metastatic disease. (PCa) . The aim of this study is to evaluate the early functional and oncological outcomes of FBT in the treatment of localized PCa.
Source of
METHODS: A retrospective review was performed at our prospective collected PCa database, searching for patients treated with FBT between 2010 and 2015. A cohort of 100 individuals treated with whole gland brachytherapy (WBT) in the same period was assessed in order to perform a comparison. IPSS, ICS and IIEF5 questionnaires were used to evaluate urinary symptoms, continence and sexual e1364 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 function, respectively, at 6, 12 and 24 months. All patients in the FBT group had a control prostate biopsy; PCa recurrence was defined as positive biopsy at the same treatment site. In the WBT group, PCa recurrence was defined by PSA increase > nadir + 2. RESULTS: Forty patients were included in the FBT group with complete oncological follow-up. Twenty-seven patients had completed questionnaires with 24 months of follow-up (included in the functional assessment). Initial presentation and treatment characteristics are exhibited on table 1. Median follow-up for FBT and WBT groups were 34 months (range: 10-68 months) and 24 months (range: 24-36 months), respectively. There was no difference in recurrence rates between-groups (FBT 7.5% vs. WBT 3%, p ¼ 0.35) ( fig. 1 ). WBT group had significant worsening of urinary symptoms when compared to FBT group at 6 months (p ¼ 0.003), but not with 12 and 24 months. Urinary continence and sexual function was similar between-groups.
CONCLUSIONS: FBT has satisfactory oncological outcomes and less urinary symptoms at early follow-up when compared to WBT. Urinary continence and sexual functional is the same as WBT.
Source of Funding: None

PD72-10 ASSESSING THE RISK OF EARLY AND LATE TOXICITY OF POST-PROSTATECTOMY RADIATION THERAPY: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS
INTRODUCTION AND OBJECTIVES: The risk of complications after radiation therapy (RT) is still controversial. Therefore, we aimed at reporting early and late genito-urinary (GU) and gastrointestinal (GI) toxicity of post-prostatectomy RT using a large multiinstitutional series.
METHODS: The study included 1196 patients treated at six tertiary referral centres with either: (i) adjuvant RT (aRT); (ii) salvage RT (sRT); (iii) RT for PSA persistence (pRT), delivered at PSA level 0.1 ng/ml within 6 months after RP. The irradiation of the pelvic lymph nodes area was left at the discretion of the treating physician. Acute and late radio-induced GU and GI complications were classified according to the RTOG/EORTC scoring system. Multivariable logistic regression analysis was used to predict the risk of grade 2 early and late GU and GI toxicity. Covariates consisted of: radiation dose, radiation field (prostatic bed vs. whole pelvis), time from RP to RT, concomitant hormonal therapy (HT), and number of lymph nodes removed during RP.
RESULTS: Overall, 281 (23%), 729 (61%), and 186 (16%) patients received aRT, sRT, and pRT, respectively. Median followup was 72 months. Overall, 658 (55%) patients had an early GU complication, of which 170 (14%) and 11 (1%) were grade 2 and 3, respectively. Similarly, 796 (67%) had an early GI complication, of which 287 (24%) and 3 (0.3%) were grade 2 and 3, respectively. Late GU complications were observed in 449 (38%) patients, of whom 140 (12%) and 72 (6%) had grade 2 and 3 events, respectively. Similarly, late GI complications were observed in 362 (30%) patients, of whom 120 (12%) and 19 (1%) had grade 2 and 3 events, respectively. At multivariable analysis, the concomitant HT administration was the only predictor that was significantly associated with both GU and GI early (OR: 2.03, p¼0.002; and OR: 1.54, p¼0.037) and late complications (OR: 2.08, p<0.001; and OR: 1.52, p¼0.01).
